roll out the news, page-140

@Oppenheimer1 No timelines have been released by apceth. It was Cynata that included these estimates in their (Cynata's) statements.

Apceth's own clinical trial of their product MSC_apceth_101 (TREAT-ME 1) had an Estimated Primary Completion Date October 2016 (https://clinicaltrials.gov/ct2/show/NCT02008539?term=NCT02008539&rank=1), being the final data collection date.

In order to proceed with our MSCs, they had to make sure that their genetically engineered MSCs (gmMSCs) work.

I now found this on their website:

"Excellent clinical safety profile

• Available clinical data from apceth Biopharma’s TREAT-ME 1 clinical trial confirm the excellent safety profile of our genetically engineered MSC."

http://www.apceth.com/gmmsc-therapy/

Not sure how long it has been on their website for, but it looks like they've now gotten the results of their trial.

In order for their product to be commercially viable, they know that their source of bone marrow won't work at large scale. Hence they made a very early move to secure the right to our Cymerus Technology, through and LOI in Dec 2015 and a binding term sheet in May 2016 - even way before their final data collection date!

And once they saw that their gmMSCs work, they could proceed "swapping" bone marrow MSCs with our iPSC derived MSCs and compare the (lab) results to see if they are the same (or better).

Bear in mind, they still have to re-do their clinical trials if they decide to go ahead with our iPSC derived MSCs.

Unfortunately they are a private company and as such don't have to report anything, not like Cynata.

That's all the info I could gather. Please correct me if I'm wrong.